Skip to content

Preloading With Nicotine Replacement Therapy in HIV-positive Smokers to Improve Self-Efficacy and Quit Attempts

Preloading With Nicotine Replacement Therapy in HIV-positive Smokers to Improve Self-Efficacy and Quit Attempts

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04994444
Enrollment
49
Registered
2021-08-06
Start date
2021-09-01
Completion date
2024-04-30
Last updated
2025-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tobacco Use Cessation

Keywords

smoking, HIV, Cessation

Brief summary

The overall goal of this research project is to examine the feasibility, acceptability, and preliminary efficacy of nicotine replacement therapy preloading (NRT-P) in HIV-positive smokers, who are struggling with cigarette dependence, urge to smoke (craving) and low self-efficacy as barriers to successful smoking cessation. Sixty participants will be recruited into a 16-week randomized pilot study. Thirty participants (control condition) will receive standard smoking cessation counseling (NRT-S) and will initiate an 8-week course of combination nicotine patch and lozenge (or gum, based on preference) on quit date (week 4), consistent with recommended guidelines based on smoking rate. Thirty participants (active condition) will start NRT patch 3 weeks prior to quit date, followed by an 8-week course of combination nicotine patch and lozenge (or gum, based on preference), initiated on quit date. The investigators will examine dependence, urge to smoke and self-efficacy for quitting prior to and following quit date. The investigators will also examine differences in quit attempts and biochemically validated smoking abstinence between the control and active conditions at weeks 8, 12, and 16.

Detailed description

Cigarette smoking is more prevalent in persons with HIV (PWH) in the U.S. when compared with the general population and is linked to increased morbidity and mortality in this population. Furthermore, HIV-positive smokers have increased rates of lung and other smoking-related cancers. Smokers with HIV are a particularly challenging group, often reporting high severity of nicotine dependence and low rates of self-efficacy for quitting, both factors related to poor smoking cessation outcomes. Establishing more effective smoking cessation approaches for smokers with HIV, particularly those that address low self-efficacy and severe dependence, is a public health priority. The overall goal of this research project is to examine the feasibility, acceptability, and preliminary efficacy of nicotine replacement therapy preloading (NRT-P) in HIV-positive smokers, who are struggling with cigarette dependence, urge to smoke (craving) and low self-efficacy as barriers to successful smoking cessation. Sixty participants will be recruited into a 12-week randomized pilot study. Thirty participants (control condition) will receive standard smoking cessation counseling (NRT-S) and will initiate an 8-week course of combination nicotine patch and lozenge on quit date (week 4), consistent with recommended guideline based on smoking rate. Thirty participants (active condition) will start NRT patch 3 weeks prior to quit date, followed by an 8-week course of combination nicotine patch and lozenge, initiated on quit date. Dependence, urge to smoke and self-efficacy for quitting prior to and following quit date will be examined. Differences in quit attempts and biochemically validated smoking abstinence between the control and active conditions at weeks 8 and 12 will also be examined. This study will be the first to examine the feasibility and initial efficacy of a novel intervention using NRT preloading to improve smoking cessation outcomes in PWH. Given the high prevalence of smoking and the significant morbidity associated with it in PWH, the development of effective strategies to reduce the risks related to smoking in this group is critical. If determined to be effective, this intervention could be readily disseminated in HIV clinics. This study will provide key information on the potential benefit of NRT preloading in a population that is highly dependent on nicotine and highly vulnerable to smoking-related morbidity and mortality.

Interventions

DRUGNicoderm CQ 21Mg/24Hr Transdermal System

Nicoderm CQ patch started 3 weeks prior to quit date. Starting on quit date, patch/gum or patch/lozenge will be used for 8 weeks. Patch will be tapered over the 8 week period.

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Brown University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

The Research Assistant collecting data at assessment sessions will not be aware of the participant's study condition.

Intervention model description

randomized clinical trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* diagnosed with HIV * at least 18 years of age * smoking at least 5 cigarettes/day * exhaled Carbon Monoxide level greater than 5 at baseline * willing to use transdermal nicotine patch * ready to quit in the next 30 days.

Exclusion criteria

* currently using pharmacotherapy for smoking cessation * medically or psychiatrically unstable (defined as: uncontrolled hypertension, unstable angina, or a medical or psychiatric hospitalization in the 30 days prior to enrollment) \*experiencing psychotic symptoms * endorsing suicidal ideation upon screening or past-year suicide attempt * pregnant or nursing.

Design outcomes

Primary

MeasureTime frameDescription
Adherence to NRTweek 12Number of days of nicotine patch use during the 8 weeks of provision

Secondary

MeasureTime frameDescription
7 Day Point Prevalence Abstinenceweek 16number of participants who reported no cigarette smoking in past 7 days

Countries

United States

Participant flow

Participants by arm

ArmCount
Preloading
Participants will be started on nicotine patch 3 weeks prior to quit date. At quit date they will use patch and lozenge or gum for 8 weeks. Nicoderm CQ 21Mg/24Hr Transdermal System: Nicoderm CQ patch started 3 weeks prior to quit date. Starting on quit date, patch/gum or patch/lozenge will be used for 8 weeks. Patch will be tapered over the 8 week period.
23
Standard Treatment
Participants will start combination nicotine replacement therapy (patch/gum or patch/lozenge) on their assigned quit date. NRT will be provided for 8 weeks. Nicoderm CQ 21Mg/24Hr Transdermal System: Nicoderm CQ patch started 3 weeks prior to quit date. Starting on quit date, patch/gum or patch/lozenge will be used for 8 weeks. Patch will be tapered over the 8 week period.
26
Total49

Baseline characteristics

CharacteristicPreloadingStandard TreatmentTotal
Age, Continuous53.0 years
STANDARD_DEVIATION 14.1
52.0 years
STANDARD_DEVIATION 11.5
52.4 years
STANDARD_DEVIATION 12.6
Cigarettes smoked per day14.1 cigarettes per day
STANDARD_DEVIATION 8.6
15.5 cigarettes per day
STANDARD_DEVIATION 9.8
14.9 cigarettes per day
STANDARD_DEVIATION 9.2
Confidence to Quit7.2 units on a scale
STANDARD_DEVIATION 2.3
7.2 units on a scale
STANDARD_DEVIATION 2
7.2 units on a scale
STANDARD_DEVIATION 2.1
Ethnicity (NIH/OMB)
Hispanic or Latino
6 Participants6 Participants12 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
17 Participants20 Participants37 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Fagerstrom test of cigarette dependence (FTCD)4.7 units on a scale
STANDARD_DEVIATION 2
4.9 units on a scale
STANDARD_DEVIATION 2.6
4.8 units on a scale
STANDARD_DEVIATION 2.3
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants1 Participants2 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
5 Participants7 Participants12 Participants
Race (NIH/OMB)
More than one race
1 Participants1 Participants2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants1 Participants1 Participants
Race (NIH/OMB)
White
16 Participants15 Participants31 Participants
Region of Enrollment
United States
23 Participants26 Participants49 Participants
Sex: Female, Male
sex
Female
9 Participants8 Participants17 Participants
Sex: Female, Male
sex
Male
14 Participants18 Participants32 Participants
Years of smoking cigarettes32.2 years
STANDARD_DEVIATION 16.5
30.0 years
STANDARD_DEVIATION 14.7
31.0 years
STANDARD_DEVIATION 15.5

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 230 / 26
other
Total, other adverse events
0 / 230 / 26
serious
Total, serious adverse events
0 / 230 / 26

Outcome results

Primary

Adherence to NRT

Number of days of nicotine patch use during the 8 weeks of provision

Time frame: week 12

ArmMeasureValue (MEAN)Dispersion
PreloadingAdherence to NRT47.4 days of NRT useStandard Deviation 13.2
Standard TreatmentAdherence to NRT32.7 days of NRT useStandard Deviation 21.8
Secondary

7 Day Point Prevalence Abstinence

number of participants who reported no cigarette smoking in past 7 days

Time frame: week 16

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Preloading7 Day Point Prevalence Abstinence4 Participants
Standard Treatment7 Day Point Prevalence Abstinence4 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026